New Delhi: Bharat Biotech has completed the Phase 2 and 3 clinical trials of coronavirus vaccine, Covaxin for use in the age group of 2 to 18 years and is expected to submit the data by next week to the DCGI.
According to the Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, ” Covaxin production would touch 55 million doses next month as against 35 million in September.”
Ella also said the Phase 2 trials of the company’s intranasal vaccine against coronavirus is expected to be over by next month.
“Paediatric Covaxin just completed phase 2/3 trials. The data analysis is going on. We will be submitting the data ( to the regulator) by next week. The number of subjects ( volunteers) is touching 1000,” he added.
“The trials for the intranasal vaccine are being conducted on about 650 volunteers, who have been grouped into three cohorts.
The first group received Covaxin as the first dose and the intranasal as the second, the second group got intranasal shots for both doses while the third group received it for the first dose and Covaxin for the second, Ella said. Each dose has been administered following a 28-day gap,” he stated.
Comments are closed.